Performance in Omics Analyses of Blood Samples in Long-Term Storage: Opportunities for the Exploitation of Existing Biobanks in Environmental Health Research

Hebels, Dennie G. A. J.; Georgiadis, Panagiotis; Keun, Hector C.; Athersuch, Toby J.; Víneis, Paolo; Vermeulen, Roel; Portengen, Lützen; Bergdahl, Ingvar A.; Hallmans, Göran; Palli, Domenico; Bendinelli, Benedetta; Krogh, Vittorio; Tumino, Rosario; Sacerdote, Carlotta; Panico, Salvatore; Kleinjans, Jos; Kok, Theo M. C. M. de; Smith, Martyn T.; Kyrtopoulos, Soterios A.

doi:10.1289/ehp.1205657

Cited by 136 publications

(146 citation statements)

References 19 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…Conversely, different media for blood samples (citrate in EPIC‐Italy and EDTA in NSHDS) might have introduced differences in cytokine levels between the two cohorts which may cause bias in unconditional analyses by incomplete correction for cohort status in the model. Although the use of different anticoagulants results in absolute differences in levels of immune markers, correlations between measurements in split samples simultaneously treated with heparin, citrate and EDTA have shown to be highly correlated 15, 30. Similarly, bias may arise from cytokine measurements of study subjects in two phases despite adjustment in multivariate analyses.…”

Section: Discussionmentioning

confidence: 99%

“…The EnviroGenoMarkers (EGM) study15 is based on participants from two existing prospective cohorts: the Italian component of the European Prospective Investigation into Cancer and Nutrition (EPIC‐Italy)16 and the Northern Sweden Health and Disease Study (NSHDS) 17. In both cohorts, blood samples were (prospectively) collected from healthy subjects at enrolment.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Pre‐diagnostic blood immune markers, incidence and progression of B‐cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses

Vermeulen¹,

Hosnijeh²,

Bodinier³

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Recent prospective studies have shown that dysregulation of the immune system may precede the development of B‐cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case–control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years before diagnosis (range 2.01–15.97) in 268 incident cases of BCL (including multiple myeloma [MM]) and matched controls. Linear mixed models and partial least square analyses were used to analyze the association between levels of immune marker and the incidence of BCL and its main histological subtypes and to investigate potential biomarkers predictive of the time to diagnosis. Linear mixed model analyses identified associations linking lower levels of fibroblast growth factor‐2 (FGF‐2 p = 7.2 × 10−4) and transforming growth factor alpha (TGF‐α, p = 6.5 × 10−5) and BCL incidence. Analyses stratified by histological subtypes identified inverse associations for MM subtype including FGF‐2 (p = 7.8 × 10−7), TGF‐α (p = 4.08 × 10−5), fractalkine (p = 1.12 × 10−3), monocyte chemotactic protein‐3 (p = 1.36 × 10−4), macrophage inflammatory protein 1‐alpha (p = 4.6 × 10−4) and vascular endothelial growth factor (p = 4.23 × 10−5). Our results also provided marginal support for already reported associations between chemokines and diffuse large BCL (DLBCL) and cytokines and chronic lymphocytic leukemia (CLL). Case‐only analyses showed that Granulocyte‐macrophage colony stimulating factor levels were consistently higher closer to diagnosis, which provides further evidence of its role in tumor progression. In conclusion, our study suggests a role of growth‐factors in the incidence of MM and of chemokine and cytokine regulation in DLBCL and CLL.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Pre‐diagnostic blood immune markers, incidence and progression of B‐cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses

Vermeulen¹,

Hosnijeh²,

Bodinier³

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Integration of different research (genomics/epigenomics, proteomics, and metabolomics) within the biobanks will strengthen biomedical and translational research [31]. Using these research capabilities for biomarker discovery, specific molecular markers for disease response can be identified, monitored, and validated [31].…”

Section: Importance Of Specialized Biobankmentioning

confidence: 99%

“…Using these research capabilities for biomarker discovery, specific molecular markers for disease response can be identified, monitored, and validated [31]. Specialized biobanks like New National Biobank of the Danish Center for Strategic Research on DD2 are an important resource to elucidate mechanisms as well as to improve the diagnosis, prognosis, and treatment.…”

Section: Importance Of Specialized Biobankmentioning

confidence: 99%

Specialized biobank for Diabetes Research: current prospect

Nawaz¹,

Usmani²,

Siddiqui³

2018

IJMDC

View full text Add to dashboard Cite

The exponential increase in human population depicted by the recent population trend shows that every 15 years the world population would increase by at least 1 billion. Consequently, there is a large increase in the use of human biospecimens for academic and pharmaceutical research. The global demand for human biospecimen is estimated to be worth $700 million and projected to increase 20%-30% annually. Biospecimens and associated data sharing are essential for biomedical research findings, discovery of disease markers, and improving patients' health care. One of the most prevalent chronic diseases worldwide that involves extensive interdisciplinary research-based studies is diabetes. In this review, we emphasized the need and importance of biobanks in diabetes, which will serve as a resource to promote research in understanding disease link, and mechanisms related to molecular pathways, protein and drug targets, and also in improving health outcomes.

show abstract

“…Como anticoagulante se emplea EDTA, ya que la heparina puede inhibir la amplificación por PCR. [15][16][17][18] Para la captura de datos, se está haciendo una migración a sistemas de gestión de información de laboratorio (LIMS, del inglés Laboratory Information Managment System, Genetadi, Biotech Vizcaya, España) que facilitan la trazabilidad de las muestras y de su información asociada. 19 El software de gestión del Biobanco además permite asegurar el anonimato de los donantes de las muestras y el acceso sólo del personal autorizado a los datos personales.…”

Section: -Toma Y Registro De Muestrasunclassified